Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

9.145 +0.085 (+0.94%)
Streaming Delayed Price Updated: 10:32 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Why Ocular Therapeutix Was Bumping Higher This Week ↗
Via The Motley Fool
News headline image
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside ↗
Needham starts coverage on Ocular Therapeutix with a Buy rating, citing Axpaxli's potential in wet AMD and forecasting $1.5 billion peak sales. 
Via Benzinga
News headline image
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback ↗
The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026. 
Via Stocktwits
News headline image
Earnings Scheduled For March 3, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
A Peek at Ocular Therapeutix's Future Earnings ↗
 
Via Benzinga
News headline image
3 Biotech Stocks to Sell in August Before They Crash & Burn ↗
Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains. 
Via InvestorPlace
News headline image
Beyond The Numbers: 8 Analysts Discuss Ocular Therapeutix Stock ↗
 
Via Benzinga
News headline image
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Deep Dive Into Ocular Therapeutix Stock: Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 14, 2024 ↗
 
Via Benzinga
News headline image
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
OCUL Stock Earnings: Ocular Therapeutix Misses EPS, Misses Revenue for Q1 2024 ↗
OCUL stock results show that Ocular Therapeutix missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
2 Small-Cap Growth Stocks With Room To Run ↗
These two small-cap growth stocks could be ready to run. 
Via The Motley Fool
News headline image
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder ↗
Ocular Therapeutix's Phase 1 HELIOS study unveils Axpaxli's efficacy in treating non-proliferative diabetic retinopathy. Significant DRSS improvement with no worsening observed. Positive Phase 2 data... 
Via Benzinga
News headline image
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
The 3 Best Biotech Stocks to Buy Now: Q2 Edition ↗
Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now. 
Via InvestorPlace
News headline image
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential ↗
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks. 
Via InvestorPlace
News headline image
Million-Dollar Bets: 3 Under-$15 Stocks With Massive Potential ↗
Here are three under-$15 stocks with massive potential based on their strategic moves in the pharmaceuticals and banking industries. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.